 Connection
Jawahar Mehta to Cardiovascular System
This is a "connection" page, showing publications Jawahar Mehta has written about Cardiovascular System.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.144 |
|
|
|
-
Romeo F, Calcaterra G, Barilla F, Mehta JL. Coronavirus disease 2019 infection and the cardiovascular system. J Cardiovasc Med (Hagerstown). 2020 06; 21(6):403-405.
Score: 0.730
-
Pothineni NV, Shirazi LF, Mehta JL. Gender Differences in Autonomic Control of the Cardiovascular System. Curr Pharm Des. 2016; 22(25):3829-34.
Score: 0.538
-
Mehta JL, Attramadal H. The TGFbeta superfamily in cardiovascular biology. Cardiovasc Res. 2007 May 01; 74(2):181-3.
Score: 0.292
-
Calcaterra G, Bassareo PP, Spaccarotella CA, Barill? F, Sciomer S, Vadal? G, de Gregorio C, Romeo F, Mehta JL, Mattioli AV. The long-term cardiovascular impairment of COVID 19: need for clarity in definition and terminology. Minerva Cardiol Angiol. 2024 Feb; 72(1):24-31.
Score: 0.229
-
Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, Greene SJ, McGuire DK, Lopes RD, Fudim M. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. Am Heart J. 2021 03; 233:86-91.
Score: 0.190
-
Dai Y, Dai D, Mercanti F, Ding Z, Wang X, Mehta JL. Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach. Acta Diabetol. 2013 Dec; 50(6):827-35.
Score: 0.113
-
Molavi B, Rasouli N, Mehta JL. Peroxisome proliferator-activated receptor ligands as antiatherogenic agents: panacea or another Pandora's box? J Cardiovasc Pharmacol Ther. 2002 Jan; 7(1):1-8.
Score: 0.051
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|